American Academy of Cannabinoid Medicine, USA
Keynote: Arch Cancer Res
CBN, cannabinol, is a mildly psychoactive cannabinoid found within the cannabis plant. We examine the very complex mechanisms that give allowance for this cannabinoids entrance into the cell membrane and its effect on cannabinoid receptors and the inhibition of the enzyme adenylate cyclase that is responsible for phosphate production. Prior study bears weight accordingly; we examine this phosphate as a potent energy source, the enzymes responsible for cell replication cycle and inhibition thereof. Moreover, how IL-2, (Interleukin-2), a type of cytokine signaling molecule in the immune system stops being produced when immune T cells are exposed to cannabinoids. How IL-2 stimulates the cell cycle via promotion of the c-Fos protein and is responsible for modulation of the immune response. This is shown by Faubert and Kaminski, that administration of CBN can slow cell replication and endure cell death (apoptosis).
Mike Robinson is Director of Communications, American Academy of Cannabinoid Medicine, Cannabinoid Medicine Research Analyst. Few out of the world of medicinal cannabis have heard his inside story, a multiple cancer survivor who used cannabis oils extensively as well for severe epilepsy, chronic Lyme disease, PTSD, and in management. Over the last 5 years he has shared his journey and analytics on cannabinoid medicine research globally while assisting patients and clinicians during his own journey. An extensive background includes being an effective leader of a large cannabis compassion program providing to the disadvantages that treated countless medicinal cannabis consumers with various alternative protocol treatments. He is a published Journalist, Research Analyst, and former Chartered Accountant in State Lobbyist 1997, pro bono non-attorney representative for children with disabilities nationwide for over 2 decades, a member of the Board of Directors for Big Brothers and Sisters, the founder of multiple non-profits that advocate/advocated for the rights of disabled children.
E-mail: [email protected]
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : August 20, 2019